{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:02:14Z","timestamp":1783497734830,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>In ulcerative colitis (UC), therapeutic goals are evolving beyond symptom control toward endoscopic and histologic healing. However, optimal strategies to achieve these targets are undefined, and the implementation of treat-to-target (T2T) in patients with minimal symptoms despite ongoing intestinal inflammation remains unexplored. This study evaluated the real-world effectiveness of endoscopy-guided optimization in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TACTIC-UC is a retrospective, single-centre study including UC patients undergoing endoscopy-guided optimization of anti-TNF agents, vedolizumab, or ustekinumab. Eligible cases had quiescent or mild symptoms (partial Mayo score 0-4) but moderate-to-severe endoscopic activity (endoscopic Mayo Score, eMS\u2009\u2265\u20092) and underwent treatment optimization within 1 month after index endoscopy. The primary outcome was mucosal healing (MH, eMS\u2009\u2264\u20091) within 1 year. Secondary endpoints included endoscopic remission (ER, eMS\u2009=\u20090), histo-endoscopic mucosal remission (HEMR, eMS\u2009=\u20090\u2009+\u2009Nancy Index\u2009=\u20090-1), biomarker trends, steroid use, adverse events, and treatment persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 164 optimization episodes were analysed in 142 patients. The 1-year cumulative probabilities of MH, ER, and HEMR were 54.2%, 28.8%, and 20.9%, respectively. In weighted analyses, anti-TNF-\u03b1 therapies outperformed non-anti-TNF-\u03b1 agents (vedolizumab and ustekinumab pooled together) across all outcomes: 66.3% versus 45.0% for MH, 39.3% versus 19.8% for ER, and 33.2% versus 8.1% for HEMR (all P-values\u2009&amp;lt;\u20090.05); consistent trends were confirmed in an exploratory 3-arm analysis incorporating synthetic data augmentation. Baseline steroid use and an eMS of 3 were independently associated with reduced probability of achieving endoscopic and histologic outcomes. No safety signals emerged. Endoscopic and histologic outcomes were associated with improved treatment persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In UC patients with quiescent or mild symptoms but active endoscopic inflammation, endoscopy-guided optimization of biologics is effective in achieving deeper inflammatory control, supporting its integration into T2T strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf239","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:59:27Z","timestamp":1766581167000},"source":"Crossref","is-referenced-by-count":2,"title":["Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis\u2014the TACTIC-UC study"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-5808","authenticated-orcid":false,"given":"Giuseppe","family":"Privitera","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Province of Milan, 20072,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Province of Milan, 20072,","place":["Italy"]},{"name":"Department of Gastroenterology, IBD Center, IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8543-4355","authenticated-orcid":false,"given":"Arianna Dal","family":"Buono","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IBD Center, IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7277-1053","authenticated-orcid":false,"given":"Roberto","family":"Gabbiadini","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IBD Center, IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Loy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IBD Center, IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ranucci","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Province of Milan, 20072,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9816-4171","authenticated-orcid":false,"given":"Luisa","family":"Bertin","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale, Universit\u00e0 Padova , Padua, 35122,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Masoni","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Province of Milan, 20072,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0198-9144","authenticated-orcid":false,"given":"Giulia","family":"Migliorisi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Province of Milan, 20072,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Sauta","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Delleani","sequence":"additional","affiliation":[{"name":"Train Srl , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Savevski","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Della Porta","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Province of Milan, 20072,","place":["Italy"]},{"name":"IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Province of Milan, 20072,","place":["Italy"]},{"name":"Department of Gastroenterology, IBD Center, IRCCS Humanitas Research Hospital , Rozzano, Province of Milan, 20089,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2026030218563449600_jjaf239-B1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"2026030218563449600_jjaf239-B2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative colitis and Crohn\u2019s disease have similar burden and goals for treatment","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026030218563449600_jjaf239-B3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026030218563449600_jjaf239-B4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026030218563449600_jjaf239-B5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","article-title":"Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2026030218563449600_jjaf239-B6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Shah","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026030218563449600_jjaf239-B7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2026030218563449600_jjaf239-B8","doi-asserted-by":"crossref","first-page":"otac020","DOI":"10.1093\/crocol\/otac020","article-title":"Real-world effectiveness of vedolizumab dose escalation in patients with inflammatory bowel disease: a systematic literature review","volume":"4","author":"Patel","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026030218563449600_jjaf239-B9","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s12325-023-02457-6","article-title":"Dose escalation patterns of advanced therapies in Crohn\u2019s disease and ulcerative colitis: a systematic literature review","volume":"40","author":"Panaccione","year":"2023","journal-title":"Adv Ther"},{"key":"2026030218563449600_jjaf239-B10","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"2026030218563449600_jjaf239-B11","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"2026030218563449600_jjaf239-B12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn\u2019s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026030218563449600_jjaf239-B13"},{"key":"2026030218563449600_jjaf239-B14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026030218563449600_jjaf239-B15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026030218563449600_jjaf239-B16","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1136\/gutjnl-2016-312722","article-title":"A practical guide to assess the Nancy histological index for UC","volume":"65","author":"Marchal-Bressenot","year":"2016","journal-title":"Gut"},{"key":"2026030218563449600_jjaf239-B17","article-title":"Synthetic data generation by artificial intelligence to accelerate research and precision medicine in hematology","volume":"7","author":"D\u2019Amico","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"2026030218563449600_jjaf239-B18","article-title":"MOSAIC: an artificial intelligence\u2013based framework for multimodal analysis, classification, and personalized prognostic assessment in rare cancers","volume":"8","author":"D\u2019Amico","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"2026030218563449600_jjaf239-B19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep remission at 1 year prevents progression of early Crohn\u2019s disease","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"key":"2026030218563449600_jjaf239-B20","first-page":"6","article-title":"A cluster randomized controlled trial of enhanced treatment algorithm for the management of Crohn\u2019s disease: REACT-2","author":"Jairath","journal-title":"United European Gastroenterol J"},{"key":"2026030218563449600_jjaf239-B21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/2050640614560785","article-title":"Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study","volume":"3","author":"Lasson","year":"2015","journal-title":"Unit Euro Gastroenterol J"},{"key":"2026030218563449600_jjaf239-B22","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cgh.2014.03.035","article-title":"Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis","volume":"12","author":"Osterman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026030218563449600_jjaf239-B23","doi-asserted-by":"crossref","first-page":"i180","DOI":"10.1093\/ecco-jcc\/jjae190.0089","article-title":"DOP050 target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe ulcerative colitis: an interim analysis from the VERDICT trial","volume":"19","author":"Jairath","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026030218563449600_jjaf239-B24","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ueg2.12714","article-title":"Disease clearance in ulcerative colitis: a narrative review","volume":"13","author":"Danese","year":"2025","journal-title":"Unit Euro Gastroenterol J"},{"key":"2026030218563449600_jjaf239-B25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030218563449600_jjaf239-B26","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.dld.2025.04.021","article-title":"Vedolizumab in inflammatory bowel disease: real-world outcomes and their prediction with machine learning\u2014the IG-IBD LIVE study","volume":"57","author":"Pugliese","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026030218563449600_jjaf239-B27","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.14309\/ajg.0000000000003212","article-title":"Effectiveness of ustekinumab for patients with moderate to severe ulcerative colitis: a multi-center real-world Canadian study","volume":"120","author":"Solitano","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026030218563449600_jjaf239-B28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"159","author":"Yoon","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf239\/66140413\/jjaf239.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/2\/jjaf239\/66140413\/jjaf239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/2\/jjaf239\/66140413\/jjaf239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:56:42Z","timestamp":1772495802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf239\/8405746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf239","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,30]]},"article-number":"jjaf239"}}